Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INV-144 vs Losartan in Hypertension and Type 2 Diabetes with Nephropathy
NCT01398423Phase 2Completed
- Sponsor
- InVasc Therapeutics, Inc.
- Start
- Jun 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of losartan + alpha lipoic acid in diabetic nephropathy (DN), hypertension (HTN), type 2 diabetes mellitus (T2DM), sponsored by InVasc Therapeutics, Inc.. Started Jun 2011; status: completed.
02
Drugs
losartan + alpha lipoic acid
03
Conditions
diabetic nephropathy (DN)hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01398423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01398423.